Rivulet Media Inc (fka RIVU)

[vegasvic]

THE FACTS ARE: READ..
Timeline

4-30-2012: Regen BioPharma, a subsidiary of BMSN, is formed.

5-8-2012: J. Christopher Mizer hired as President and COO.

6-6-2012: David White MD, Wei-Ping Min MD/PHD, and Vald Bogin MD are appointed as members of the Scientific Advisory Board.

6-7-2012: Granted access to patent for stimulating blood cell production with stem cells.

6-15-2012: David Audley joins the advisory board.

6-26-2012: Thomas E. Ichim PhD joins as Chief Scientific Officer and Director of Research.

10-29-2012: BMSN participates in the 2012 Stem Cell Meeting on the Mesa. There, J. Christopher Mizer explains their business plan. Check it out!

11-19-2012: Pre-Clinical study for HemaXellerate begins.

1-24-2013: Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate.

2-5-2013: Investigational New Drug (IND) Application is filed with the FDA for HemaXellerate.

2-26-2013: A Letter of Intent (LOI) is entered into to purchase a patent for a gene silencing treatment for breast cancer.

3-12-2013: BMSN settles an old lawsuit it had.

3-18-2013: Receives the IND # from the FDA for HemaXellerate.

3-22-2013: All SEC financials are brought up-to-date and BMSN is up-listed from the Pinks to the OTC-QB.


Where we're at now

BE PATIENT…I doubt all this effort just to be a scam.